RA
PROF

Royce & Associates’s Profound Medical PROF Stock Holding History

Royce & Associates’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.98M Buy
1,199,564
+83,216
+7% +$559K 0.06% 420
2026
Q1 		$7.14M Buy
1,116,348
+126,000
+13% +$870K 0.07% 409
2025
Q4 		$7.77M Buy
990,348
+130,442
+15% +$838K 0.08% 384
2025
Q3 		$4.2M Buy
859,906
+95,000
+12% +$485K 0.04% 495
2025
Q2 		$4.55M Buy
764,906
+3,107
+0.4% +$16.4K 0.05% 478
2025
Q1 		$4.35M Sell
761,799
-3,000
-0.4% -$20.7K 0.05% 469
2024
Q4 		$5.75M Buy
764,799
+195,501
+34% +$1.5M 0.05% 453
2024
Q3 		$4.53M Buy
569,298
+3,500
+0.6% +$31.6K 0.04% 495
2024
Q2 		$4.85M Buy
565,798
+1,500
+0.3% +$12.1K 0.05% 487
2024
Q1 		$4.76M Hold
564,298
– – 0.04% 500
2023
Q4 		$4.73M Sell
564,298
-5,600
-1% -$53.2K 0.04% 501
2023
Q3 		$5.71M Buy
569,898
+3,900
+0.7% +$40.4K 0.06% 452
2023
Q2 		$7.25M Sell
565,998
-5,100
-0.9% -$63.3K 0.07% 408
2023
Q1 		$5.29M Buy
571,098
+22,900
+4% +$265K 0.05% 470
2022
Q4 		$5.86M Buy
548,198
+103,300
+23% +$563K 0.06% 417
2022
Q3 		$1.8M Sell
444,898
-58,000
-12% -$391K 0.02% 644
2022
Q2 		$3.67M Sell
502,898
-2,100
-0.4% -$16.6K 0.04% 558
2022
Q1 		$4.54M Sell
504,998
-61,500
-11% -$592K 0.04% 569
2021
Q4 		$6.39M Buy
566,498
+48,898
+9% +$611K 0.05% 504
2021
Q3 		$7.56M Buy
517,600
+41,000
+9% +$625K 0.06% 486
2021
Q2 		$7.76M Buy
476,600
+18,200
+4% +$339K 0.05% 496
2021
Q1 		$9.19M Buy
458,400
+157,400
+52% +$3.77M 0.06% 469
2020
Q4 		$6.19M Buy
301,000
+291,000
+2,910% +$5.35M 0.05% 505
2020
Q3 		$176K Sell
10,000
-283,000
-97% -$4.5M ﹤0.01% 943
2020
Q2 		$4.96M Hold
293,000
– – 0.05% 462
2020
Q1 		$2.82M Buy
293,000
+98,000
+50% +$1.27M 0.04% 515
2019
Q4 		$2.21M Buy
+195,000
New +$1.8M 0.02% 681

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.77B AUM 38.11% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
RMC
Ring Mountain Capital Tiburon, California $238M AUM 61.63% 1-Year Est. Return

Royce & Associates's PROF Position: Q2 2026 in Review

Royce & Associates increased its Profound Medical (PROF) stake by 7.5% in Q2 2026, buying an estimated $559K and bringing the position to 1,199,564 shares worth $7.98M. The position accounts for 0.06% of the portfolio, ranked #420.

Royce & Associates first reported a position in PROF in Q4 2019 and has held it in 27 quarters since. The position peaked at $9.19M in Q1 2021. 56 funds tracked by Wall St. Rank hold PROF as of Q2 2026.

  • Royce & Associates held 1,199,564 shares of Profound Medical worth $7.98M as of Q2 2026.
  • Royce & Associates bought 83,216 Profound Medical shares in Q2 2026, an estimated $559K.
  • Profound Medical made up 0.06% of Royce & Associates's portfolio in Q2 2026, its #420 holding.
  • Royce & Associates first reported a position in Profound Medical in Q4 2019 and has held it in 27 quarters since.
  • Royce & Associates's Profound Medical position peaked at $9.19M in Q1 2021.
  • 56 funds tracked by Wall St. Rank held Profound Medical as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.